Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
| ▸ | HRH1 | P35367 | 2/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4960243 | 0.90 | CHRNA7 (0.55) | CYP2A6HRH1CHRNA7CYP3A4CYP2D6 | |
| SCHEMBL18896391 | 0.84 | TDP1 (0.60) | CYP2A6CHRNA7CYP2D6FDPSTDP1 | |
| SCHEMBL7288023 | 0.83 | CHRNA7 (0.53) | CYP2A6HRH1CHRNA7CYP3A4CYP2D6 | |
| SCHEMBL19737206 | 0.83 | CHRNA7 (0.53) | CYP2A6HRH1CHRNA7CYP3A4CYP2D6 | |
| SCHEMBL19334178 | 0.83 | TDP1 (0.58) | HRH1FDPSTDP1L3MBTL1CHRNB2 | |
| SCHEMBL4959182 | 0.82 | FDPS (0.45) | CYP2A6HRH1CHRNA7CYP3A4CYP2D6 | |
| SCHEMBL18934268 | 0.81 | TDP1 (0.51) | CHRNA7CYP2D6FDPSTDP1L3MBTL1 | |
| SCHEMBL4957549 | 0.81 | CYP2D6 (0.44) | CHRNA7CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL19628486 | 0.79 | TAAR1 (0.52) | CYP2A6HRH1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL8217779 | 0.78 | CHRNB2 (0.50) | CHRNA7CYP2D6FDPSTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020032206-A1 | Pharmaceutical compositions for prevention and treatment of central nervous system disorders | CALDWELL WILLIAM SCOTT (US) | 2002-03-14 | — | — | US | claimed |
| EP-0900200-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-03-10 | — | — | EP | claimed |
| WO-1997040011-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R. J. REYNOLDS TOBACCO COMPANY (US) | 1997-10-30 | — | — | WO | claimed |
| EP-1997806-A1 | Pahrmaceutical compositions for prevention and treatment of central nervous system disorders | Targacept, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| US-6603011-B1 | Representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine; the prevention and treatment of CNS disorders which have been attributed to neurotransmitter system dysfunction | TARGACEPT, INC. | 2003-08-05 | — | — | US | disclosed |
| US-6555684-B2 | A pyridine or pyrimidine derivatives containing primary, secondary or tertiary amine group | TARGACEPT, INC. | 2003-04-29 | — | — | US | disclosed |
| US-20020032206-A1 | Pharmaceutical compositions for prevention and treatment of central nervous system disorders | CALDWELL WILLIAM SCOTT (US) | 2002-03-14 | — | — | US | disclosed |
| US-5616716-A | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds | TARGACEPT, INC. | 1997-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032206-A1 | Pharmaceutical compositions for prevention and treatment of central nervous system disorders | PMP22, AANAT, CHAT | CYP2A6 172/4885HRH1 330/4885CHRNA7 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.